Interventricular septal dissecting haematoma.

153–160. 20. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM; ILLUSTRATE Investigators. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356: 1304–1316. 21. Barter PJ, Caufield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357: 2109–2122. 22. Mazzone T. HDL cholesterol and atherosclerosis. Lancet 2007;370:107–108. 23. Rader DJ. Illuminating HDL – Is it still a viable therapeutic target? N Engl J Med 2007;357:2180–2183. 24. Lavie CJ, Milani RV. Shedding light on high-density lipoprotein cholesterol – The post-ILLUMINATE era. J Am Coll Cardiol 2008;51:56–58. 25. Mehta RH, Roe MT, Chen AY, Lytle BL, Pollack CV Jr, Brindis RG, Smith SC Jr, Harrington RA, Fintel D, Fraulo ES, Califf RM, Gibler WB, Ohman EM, Peterson ED. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. Arch Int Med 2006;166:2027–2034.